Tag Archives: Cancer Research

No Revenue, No Problem: Illuminating Illumina’s Blocked Acquisition of GRAIL (and What the Netherlands Has to Do With It)

On October 28, 2022, European Union (EU) regulators renewed interim measures ordering Illumina to keep GRAIL as a separate entity following Illumina’s September 2020 acquisition of the cancer detection company. Illumina jumped the gun and acquired GRAIL before obtaining approval from EU antitrust regulators under the EU Merger Regulation (EUMR). Failure to comply with the interim measures could result […]